Aqua Medical, Inc. announced the presentation of 12-month follow-up clinical data from outside the US for its radiofrequency vapor ablation platform at Digestive Disease Week 2026. The data highlighted its PIMA procedure for type 2 diabetes.
Aqua Medical announced that the FDA granted IDE approval for a pilot clinical trial of its PIMA procedure using its radiofrequency vapor ablation platform.
Aqua Medical’s leadership team includes Robert “Bob” Haggerty, Virender K. Sharma, MD, and Scott McGill. Haggerty has more than 35 years of medical device leadership experience, including over three decades in gastroenterology.
Aqua Medical’s through-the-endoscope, 30-minute outpatient treatment represents an intervention to enhance control for individuals with type 2 diabetes.
Aqua Medical raises a Series B led by Relevance Ventures to advance U.S. studies of its investigational PIMA procedure for Type 2 diabetes. The funding will support completion of the RESTORE-1 pilot study and preparation for a planned U.S. pivotal trial. PIMA is described as a novel through-the-scope procedure.
Aqua Medical appoints medical device executive Bob Haggerty as president and CEO, effective July 31, 2026. The appointment is framed as part of the company’s effort to take on type 2 diabetes.
Aqua Medical treats the first U.S. patient in its FDA-authorized IDE trial at UNC Health. The patient receives the investigational PIMA procedure, a through-the-scope endoscopic therapy for type 2 diabetes.
Aqua Medical presented 12-month clinical follow-up data for its PIMA procedure at Digestive Disease Week 2026. The headline reports 100% insulin elimination for 12 months in patients with type 2 diabetes.